In vitro and in vivo evaluation of paclitaxel–lapatinib-loaded F127 pluronic micelles

References

• Stevanovic A, Lee P, Wilcken N. Metastatic breast cancer. Aust Fam Physician 2006;35:309.
   PubMedGoogle Scholar
• Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340–58.
   PubMed Web of Science ®Google Scholar
• Coates A, Abraham S, Kaye SB, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203–8.
   PubMedGoogle Scholar
• Zhao Y, Alakhova DY, Kabanov AV. Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev 2013;65:1763–83.
   PubMed Web of Science ®Google Scholar
• Kwon GS, Kataoka K. Block copolymer micelles as long-circulating drug vehicles. Adv Drug Deliv Rev 1995;16:295–309.
   Web of Science ®Google Scholar
• Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 1996;21:107–16.
   Web of Science ®Google Scholar
• Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007;24:1–16.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008;130:98–106.
   PubMed Web of Science ®Google Scholar
• De Brabander M, Geuens G, Nuydens R, et al. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci 1981;78:5608–12.
   PubMed Web of Science ®Google Scholar
• Mullan PB, Quinn JE, Gilmore PM, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20:6123–31.
   PubMed Web of Science ®Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008;30:1426–47.
   PubMed Web of Science ®Google Scholar
• Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012;2012:915375.
   Google Scholar
• Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010;16:1509–19.
   PubMed Web of Science ®Google Scholar
• Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010;16:34–44.
   PubMed Web of Science ®Google Scholar
• Dai C-l, Tiwari AK, Wu C-P, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905–14.
   PubMed Web of Science ®Google Scholar
• Collins D, Crown J, O’Donovan N, et al. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Invest New Drugs 2010;28:433–44.
   PubMed Web of Science ®Google Scholar
• Perry J, Ghazaly E, Kitromilidou C, et al. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. Mol Cancer Ther 2010;9:3322–9.
   PubMed Web of Science ®Google Scholar
• Wei Y, Xu S, Wang F, et al. A novel combined micellar system of lapatinib and paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor‐2 positive breast tumor in vitro. J Pharm Sci 2015;104:165–77.
   PubMed Web of Science ®Google Scholar
• Alani AW, Bae Y, Rao DA, Kwon GS. Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel. Biomaterials 2010;31:1765–72.
   PubMed Web of Science ®Google Scholar
• Yan F, Li L, Deng Z, et al. Paclitaxel-liposome loaded microbubbles for ultrasound-triggered drug delivery in vitro and in vivo. J Acoust Soc Am 2012;131:3366.
   Google Scholar
• Sheihet L, Garbuzenko OB, Bushman J, et al. Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor. Eur J Pharm Sci 2012;45:320–9.
   PubMed Web of Science ®Google Scholar
• Teow HM, Zhou Z, Najlah M, et al. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm 2013;441:701–11.
   PubMed Web of Science ®Google Scholar
• Gao H, Cao S, Chen C, et al. Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer. Nanomedicine (Lond) 2013;8:1429–42.
   PubMed Web of Science ®Google Scholar
• Li F, Danquah M, Singh S, et al. Paclitaxel-and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. Drug Deliv Transl Res 2011;1:420–8.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271–84.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002;82:189–212.
   PubMed Web of Science ®Google Scholar
• Dehghan Kelishady P, Saadat E, Ravar F, et al. Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation. Pharm Dev Technol 2015;20:1009–17.
   PubMed Web of Science ®Google Scholar
• Saadat E, Kelishady PD, Ravar F, et al. Development and validation of rapid stability-indicating RP-HPLC-DAD method for the quantification of lapatinib and mass spectrometry analysis of degraded products. J Chromatogr Sci 2015;53:932–9.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630–9.
   PubMed Web of Science ®Google Scholar
• Werner ME, Cummings ND, Sethi M, et al. Preclinical evaluation of genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013;86:463–8.
   PubMed Web of Science ®Google Scholar
• Yoncheva K, Calleja P, Agüeros M, et al. Stabilized micelles as delivery vehicles for paclitaxel. Int J Pharm 2012;436:258–64.
   PubMed Web of Science ®Google Scholar
• Zhang L, Fan C, Guo Z, et al. Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer. Eur J Med Chem 2013;69:833–41.
   PubMed Web of Science ®Google Scholar
• Cheon Lee S, Kim C, Chan Kwon I, et al. Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(epsilon-caprolactone) copolymer as a carrier for paclitaxel. J Control Release 2003;89:437–46.
   PubMed Web of Science ®Google Scholar
• Rapoport N, Marin A, Luo Y, et al. Intracellular uptake and trafficking of Pluronic micelles in drug-sensitive and MDR cells: effect on the intracellular drug localization. J Pharm Sci 2002;91:157–70.
   PubMed Web of Science ®Google Scholar
• Minko T, Batrakova EV, Li S, et al. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release 2005;105:269–78.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Brynskikh AM, et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release 2010;143:290–301.
   PubMed Web of Science ®Google Scholar
• O'Connor R. The pharmacology of cancer resistance. Anticancer Res 2007;27:1267–72.
   PubMed Web of Science ®Google Scholar
• Dehghan Kelishady P, Saadat E, Ravar F, et al. Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation. Pharm Dev Technol 2015;20:1009–17.
   PubMed Web of Science ®Google Scholar
• Danson S, Ferry D, Alakhov V, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004;90:2085–91.
   PubMed Web of Science ®Google Scholar
• Lilletvedt M, Smistad G, Tønnesen H, et al. Solubilization of the novel anionic amphiphilic photosensitizer TPCS 2a by nonionic Pluronic block copolymers. Eur J Pharm Sci 2011;43:180–7.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang T, Zhou Z, et al. Enhanced uptake and cytotoxity of folate-conjugated mitoxantrone-loaded micelles via receptor up-regulation by dexamethasone. Int J Pharm 2013;448:142–9.
   PubMed Web of Science ®Google Scholar
• Tavassolian F, Kamalinia G, Rouhani H, et al. Targeted poly (l-γ-glutamyl glutamine) nanoparticles of docetaxel against folate over-expressed breast cancer cells. Int J Pharm 2014;467:123–38.
   PubMed Web of Science ®Google Scholar
• Pan J, Feng S-S. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 2008;29:2663–72.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Feng S-S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006;27:4025–33.
   PubMed Web of Science ®Google Scholar
• Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 2003;3:571–81.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Vinogradov SV, et al. Mechanism of pluronic effect on P-glycoprotein efflux system in blood–brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001;299:483–93.
   PubMed Web of Science ®Google Scholar
• Huo M, Zou A, Yao C, et al. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 2012;33:6393–407.
   PubMed Web of Science ®Google Scholar
• Kim J-H, Bae SM, Na M-H, et al. Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues. J Control Release 2012;157:493–9.
   PubMed Web of Science ®Google Scholar
• Xiao K, Luo J, Fowler WL, et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 2009;30:6006–16.
   PubMed Web of Science ®Google Scholar
• Davis ME. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771–82.
   PubMed Web of Science ®Google Scholar
• Chen L, Sha X, Jiang X, et al. Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation. Int J Nanomed 2013;8:73.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhang L. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P1231. Acta Pharmacol Sin 2006;27:747–53.
   PubMed Web of Science ®Google Scholar
• Shen J, Sun H, Xu P, et al. Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Biomaterials 2013;34:1581–90.
   PubMed Web of Science ®Google Scholar
• Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399–405.
   PubMed Web of Science ®Google Scholar
• Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res 2000;2:1.
   Web of Science ®Google Scholar